Clinical and Translational Oncology

, Volume 11, Issue 8, pp 499–510

Comprehensive lung injury pathology induced by mTOR inhibitors

  • Guadalupe Aparicio
  • Moisés B. Calvo
  • Vanessa Medina
  • Ovidio Fernández
  • Paula Jiménez
  • Martina Lema
  • Angélica Figueroa
  • Luis M. Antón Aparicio
Educational Series Molecular Targets in Oncology

DOI: 10.1007/s12094-009-0394-y

Cite this article as:
Aparicio, G., Calvo, M.B., Medina, V. et al. Clin Transl Oncol (2009) 11: 499. doi:10.1007/s12094-009-0394-y

Abstract

Interstitial lung disease is a rare side effect of temsirolimus treatment in renal cancer patients. Pulmonary fibrosis is characterised by the accumulation of extracellular matrix collagen, fibroblast proliferation and migration, and loss of alveolar gas exchange units. Previous studies of pulmonary fibrosis have mainly focused on the fibro-proliferative process in the lungs. However, the molecular mechanism by which sirolimus promotes lung fibrosis remains elusive. Here, we propose an overall cascade hypothesis of interstitial lung diseases that represents a common, partly underlying synergism among them as well as the lung pathogenesis side effects of mammalian target of rapamycin inhibitors.

Keywords

Interstitial lung disease Pulmonary fibrosis Sirolimus ROS Rapamycin 

Copyright information

© Feseo 2009

Authors and Affiliations

  • Guadalupe Aparicio
    • 1
  • Moisés B. Calvo
    • 2
  • Vanessa Medina
    • 1
  • Ovidio Fernández
    • 3
  • Paula Jiménez
    • 4
  • Martina Lema
    • 5
  • Angélica Figueroa
    • 2
  • Luis M. Antón Aparicio
    • 3
    • 6
  1. 1.Oncology Research LabINIBICA CoruñaSpain
  2. 2.INIBICA Coruña University HospitalA CoruñaSpain
  3. 3.Medical Oncology ServiceA Coruña University HospitalA CoruñaSpain
  4. 4.Medical Oncology ServiceAsturias Central HospitalOviedoSpain
  5. 5.Pharmacy ServiceA Coruña University HospitalA CoruñaSpain
  6. 6.Medicine DepartmentUniversity of A CoruñaA CoruñaSpain